Pralsetinib

Introduction Overview

Generic Name

pralsetinib

Brand Name

Gavreto

Dosage Form

oral capsule

Drug Class

Multikinase inhibitors

Pharmacokinetics

Absorption: Pralsetinib (Gavreto) is administered orally in the form of capsules and is recommended to be taken on an empty stomach, at least 1 hour before or 2 hours after meals, to optimize absorption. The bioavailability is influenced by food intake which may alter plasma concentrations, hence the strict recommendation to dose fasting. Pharmacokinetic studies demonstrate that pralsetinib reaches peak plasma concentrations generally within a few hours after oral administration. Distribution: Pralsetinib exhibits extensive distribution throughout body tissues, facilitated by its lipophilic nature. Plasma protein binding is moderate to high, which impacts its distribution volume and free drug concentration. Distribution to tumor tissues has been confirmed in preclinical models, correlating with clinical efficacy in RET fusion-positive malignancies. The drug's ability to cross the blood-brain barrier has not been extensively characterized but is clinically relevant in cancers with potential CNS involvement. Metabolism: The metabolism of pralsetinib occurs primarily in the liver, predominantly through the cytochrome P450 enzyme CYP3A isoform. This biotransformation results in various metabolites, some with minimal pharmacological activity. CYP3A-mediated metabolism facilitates pralsetinib's clearance but also renders it susceptible to interactions with CYP3A inhibitors or inducers. Clinical studies confirm that coadministration with strong CYP3A inhibitors increases pralsetinib plasma levels, necessitating dosage adjustments, whereas CYP3A inducers reduce plasma concentrations potentially compromising efficacy. Elimination: Pralsetinib and its metabolites are primarily eliminated via hepatic routes with biliary excretion, while renal clearance plays a minor role. The elimination half-life supports once-daily dosing, typically around 12 to 18 hours, allowing for sustained plasma concentrations over 24 hours. Dose adjustments may be required in hepatic impairment due to reduced metabolism and clearance. Clinical pharmacokinetic data also highlight the necessity for frequent monitoring of liver function tests during therapy to detect any hepatic adverse effects or changes impacting drug clearance.

Dosage Forms

Available Dosage Forms: Gavreto is provided exclusively as oral capsules, with each capsule containing 100 mg of the active ingredient pralsetinib. The capsules are supplied in bottles containing 60, 90, or 120 capsules. Dosages for Adults and Adolescents: The standard therapeutic dosage for adults and children aged 12 years and over is 400 mg taken orally once daily, equating to four 100 mg capsules daily. This dosing regimen is established based on clinical efficacy and safety data for RET fusion-positive metastatic cancers. Specific Patient Populations: For pediatric patients younger than 12 years of age and for use in children for NSCLC treatment, safety and efficacy have not been established. Furthermore, patients requiring dose modification due to adverse effects or concomitant interacting drugs (e.g., CYP3A inhibitors or inducers) may need individual dosage adjustments under medical supervision. The capsules must be swallowed whole and not opened, broken, or chewed. Given the pharmacodynamic considerations, treatment with Gavreto requires regular monitoring including blood work and blood pressure checks to guide dosing and detect toxicity. The recommended administration is on an empty stomach to maximize absorption, emphasizing patient adherence to the timing of dosing relative to meals.

Mechanism Of Action

Pralsetinib is a highly selective RET (rearranged during transfection) kinase inhibitor designed to target cancers driven by aberrant RET gene alterations, including gene fusions and mutations. RET is a receptor tyrosine kinase that regulates cell proliferation, differentiation, and survival through various downstream signaling pathways such as MAPK, PI3K/AKT, and JAK/STAT. In malignancies harboring RET fusions or mutations, the constitutive activation of the RET kinase domain leads to oncogenic transformation and tumor progression. Pralsetinib binds to the ATP-binding pocket of the RET kinase domain, competitively inhibiting its phosphorylation activity, thereby blocking downstream signaling cascades vital for tumor cell survival and proliferation. This targeted inhibition induces tumor cell apoptosis and suppresses tumor growth. The molecular specificity of pralsetinib for RET over other kinases confers an improved safety profile relative to less selective multikinase inhibitors. Clinical trials demonstrate pralsetinib’s efficacy in RET fusion-positive non-small cell lung cancer (NSCLC) and RET-mutant advanced thyroid cancers, even in patients previously treated with other systemic therapies. Comparative mechanistically, pralsetinib shares similarities with other RET inhibitors such as selpercatinib but exhibits distinct pharmacokinetic and selectivity profiles contributing to differential therapeutic activity and adverse effect profiles. Emerging research indicates sustained responses and favorable resistance profiles with pralsetinib, highlighting its role as a cornerstone in precision oncology for RET-driven cancers.

Pharmacological Actions

Selective inhibition of RET receptor tyrosine kinase activity.
Suppression of oncogenic RET fusion and mutation-driven signaling pathways.
Induction of apoptosis and growth arrest in RET-dependent cancer cells.
Blockage of downstream MAPK, PI3K/AKT, and JAK/STAT signaling cascades.
Antitumor activity in RET fusion-positive non-small cell lung carcinoma.
Efficacy in advanced medullary thyroid carcinoma and RET-mutant thyroid cancers.
Reduction of tumor burden with oral administration enabling outpatient therapy.
Minimization of off-target kinase inhibition due to high selectivity for RET.
Modulation of tumor microenvironment indirectly via tumor cell apoptosis.
Demonstrated activity in RET-driven metastatic disease refractory to prior therapy.
Potential to delay progression and improve overall survival in target populations.
Pharmacodynamic effects monitored by reduction of tumor markers and imaging.
Synergistic potential with other anticancer agents under clinical investigation.
Capability to overcome resistance mutations in RET kinase domain in some cases.

Therapeutic Or Clinical Uses

Treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adults.
Management of advanced or metastatic thyroid cancers with RET mutations or fusions in adults.
Use in pediatric patients aged 12 and older with RET fusion-positive thyroid cancer requiring systemic therapy.
Second-line therapy option when radioactive iodine fails in differentiated thyroid cancer.
Targeted therapy for RET-driven malignancies allowing personalized cancer treatment.
Off-label considerations in clinical trials for other RET-associated tumors.
Potential treatment for patients intolerant or resistant to conventional chemotherapy.
Adjunct therapy to conventional oncologic treatments in RET altered cancers.
Monotherapy to reduce tumor size and control disease progression in eligible patients.
Patient-specific therapy based on molecular diagnostic confirmation of RET alterations.
An alternative to multi-targeted kinase inhibitors with broader side-effect profile.
Treatment approach that delays disease progression in metastatic RET fusion cancers.
Management of cancers with limited standard therapeutic options targeting RET.
Foundation drug in precision oncology protocols for RET aberrations.

Side Or Adverse Effects

Muscle or joint pain (myalgia, arthralgia).
Gastrointestinal disturbances including constipation and diarrhea.
Hypertension, sometimes severe, requiring regular blood pressure monitoring.
Edema presenting as swelling of face, arms, legs, hands, and feet.
Fatigue and general feeling of tiredness.
Fever episodes during therapy.
Cough and respiratory symptoms related to lung effects.
Laboratory abnormalities such as low blood cell counts (leukopenia, anemia, thrombocytopenia).
Electrolyte imbalances including low sodium, phosphate, calcium, and potassium levels.
Elevations in liver enzymes indicating potential hepatic toxicity.
Serious bleeding events manifesting as vomiting blood, hematuria, or unusual bruising.
Lung inflammation (pneumonitis) which can be life-threatening if untreated.
Tumor Lysis Syndrome presenting with nausea, vomiting, weakness, and seizures.
Allergic hypersensitivity reactions including hives and swelling of face or throat.
Potential impact on wound healing delaying post-surgical recovery.

Precautions

Regular monitoring of blood pressure due to risk of hypertension.
Frequent blood tests to assess blood counts and liver function during treatment.
Avoidance of use prior to surgery and discontinuation at least 5 days before planned surgery.
Close observation for signs of lung inflammation; prompt reporting of respiratory symptoms.
Hydration monitoring to prevent and manage tumor lysis syndrome.
Assessment of bleeding risk and vigilance for any signs of abnormal bleeding.
Consultation regarding fertility concerns as pralsetinib may impair reproductive ability.
Use barrier contraception methods in patients of reproductive potential during and post therapy.
Avoidance of grapefruit and other CYP3A-modulating substances due to drug interactions.
Consideration of drug-drug interactions particularly with CYP3A and P-gp inhibitors/inducers.
Regular hepatic function tests given potential for elevated liver enzymes.
Patient education about adverse effects, signs of serious reactions, and dose adherence.
Monitoring for electrolyte disturbances and correction as clinically indicated.
Cautious use in patients with pre-existing liver or cardiovascular conditions.
Avoid breastfeeding during treatment and for one week after last dose.

Warnings

Risk of severe or life-threatening pneumonitis; immediate evaluation of respiratory symptoms required.
Potential for severe hypertension, possibly necessitating antihypertensive therapy adjustments.
Liver toxicity with elevated transaminases; liver function must be closely monitored.
Serious bleeding events including fatal hemorrhages reported; monitor coagulation status.
Tumor Lysis Syndrome risk due to rapid tumor cell destruction; hydration and monitoring necessary.
Impaired wound healing; discontinue drug prior to surgery and resume only after adequate recovery.
Hypersensitivity and anaphylaxis possible; emergency medical intervention may be necessary.
Potential harm to an unborn fetus; strict contraception required for reproductive-age patients.
Unknown safety profile in children under 12 for thyroid cancer and NSCLC treatment.
Avoid coadministration with strong CYP3A inhibitors or inducers unless dose adjustment is feasible.
Do not initiate treatment without confirming RET gene alteration status.
Possible effects on growth plates in pediatric patients impacting bone development.
Risk of serious adverse events warrants treatment under specialized oncology care.
Use caution in patients with existing cardiovascular comorbidities due to risk of heart-related adverse effects.
Emergency management advised for any signs of allergic reactions including facial or airway swelling.

Contraindication

Known hypersensitivity to pralsetinib or any component of the formulation.
Concomitant use with strong CYP3A inhibitors or inducers without appropriate dose adjustment.
Patients with uncontrolled or severe hepatic impairment due to metabolism concerns.
Pregnancy due to potential teratogenic effects and risk of fetal harm.
Patients unable to comply with required monitoring and dosing schedules.
Use in children under 12 years of age for RET fusion-positive cancers due to insufficient safety data.
Patients with active severe bleeding disorders without adequate management.
Individuals with a history of severe allergic reactions to multikinase inhibitors.
Concurrent use with medications that have serious interactions increasing toxicity risk.
Patients with untreated or unstable hypertension at initiation of therapy.
Use in patients with significant pulmonary conditions without proper risk assessment.
Severe bone marrow suppression as pralsetinib may exacerbate cytopenias.
Presence of unhealed surgical wounds or recent major surgery without appropriate clearance.
Combination with therapies that may compound risk of liver injury without monitoring.
Patients with hypersensitivity to capsule excipients such as FD&C Blue #1.

Drug Interactions

Strong or moderate CYP3A inhibitors (e.g., clarithromycin, erythromycin, itraconazole, ketoconazole) increase pralsetinib plasma levels, potentially intensifying adverse effects.
Strong or moderate CYP3A inducers (e.g., phenobarbital, phenytoin, rifampicin, St. John's Wort) decrease pralsetinib levels and may reduce efficacy.
P-glycoprotein (P-gp) inhibitors can increase pralsetinib exposure altering safety profile.
Concomitant use with certain antibiotics and antifungals may alter pralsetinib pharmacokinetics.
Antiviral agents used in HIV or hepatitis C treatment may interact via CYP3A pathways.
Some cholesterol-lowering agents (statins) could have interactions enhancing toxicity.
Seizure medications such as phenytoin can reduce pralsetinib concentrations.
Drugs affecting liver enzyme function may modify pralsetinib metabolism.
Avoid grapefruit and grapefruit juice due to CYP3A inhibition increasing drug levels.
Co-administration with other cancer therapies requires careful evaluation for additive toxicity.
Combination with anticoagulants may amplify bleeding risk.
Concomitant use with immunosuppressants necessitates monitoring for immunomodulatory effects.
Potential interactions with herbal products, including goldenseal and St. John's Wort.
Co-administration with drugs that alter electrolyte balance may compound adverse effects.
Not all drug interactions are fully characterized; continuous pharmacovigilance is recommended.

Preparations Of The Drug

Gavreto 100 mg oral capsules containing active pharmaceutical ingredient pralsetinib.
Capsule formulation includes inactive ingredients: citric acid, hydroxypropyl methylcellulose (HPMC), magnesium stearate, microcrystalline cellulose (MCC), pregelatinized starch, and sodium bicarbonate for stability and bioavailability.
Capsule shell components: FD&C Blue #1 (Brilliant Blue FCF), hypromellose, titanium dioxide, providing uniform appearance and capsule integrity.
White printing ink on the capsule containing butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac, strong ammonia solution, and titanium dioxide for identification.
Available in various bottle sizes: 60, 90, and 120 capsules to accommodate treatment duration.
Oral capsules are designed for swallowing whole, preserving dose accuracy.
Packaging protects against moisture and heat; storage recommended at controlled room temperature (68°F to 77°F or 20°C to 25°C).
Manufactured by Rigel Pharmaceuticals, Inc. under stringent quality controls.
The drug is supplied with patient information leaflets detailing administration, storage, and safety.
Prepared specifically for targeted oncology use with considerations for pediatric and adult formulations.
Manufacturing process includes purification to ensure consistency and potency of pralsetinib across batches.
Capsule design facilitates ease of use and patient compliance in outpatient cancer therapy.
Formulation parameters optimized to enhance shelf life and maintain chemical stability.
Inactive excipients chosen to minimize allergic potential and ensure tolerability.
Compliant with regulatory standards for FDA-approved oral oncology medications.